Tiger and Gaudi Clinical develop vacuum-insulated cell transport pod

Tiger Corporation, the Japanese maker of vacuum flasks, and the regenerative medicine company Gaudi Clinical have jointly developed the Vacuum-Insulated Cell Pod (真空断熱セルポッド), a container for transporting cells and other medical specimens, and announced it through PR TIMES. The container is small, about 10 cm in diameter and 18 cm tall. According to the companies, it held a 20°C range, close to room temperature, for 24 hours and a 5°C range, close to refrigeration, for 11.5 hours. The aim is to deliver cells by train and other public transport, or by hand carry, rather than by dedicated temperature-controlled vehicles. The companies are aiming for practical use in 2027.

The container uses the stainless steel vacuum insulation that Tiger has long used in its flasks and bottles: a double stainless wall with a vacuum in the gap. Air in the gap would carry heat across, so without it outside heat and cold barely get in. Inside, a latent heat storage material holds the temperature. It melts or freezes at a set temperature and keeps that temperature while the change goes on. The container and storage material together weigh about 700 g. A vacuum layer insulates far better than foam of the same thickness, so less storage material and a smaller container suffice for the same hold time.

Unfrozen transport has usually meant a temperature-controlled vehicle or a foam box packed with cold packs. The pod is meant for cells that are not frozen. Cryopreserved cells such as CAR-T travel in liquid nitrogen containers instead.

Cells keep metabolizing after collection, so developers set a maximum time from collection to the processing facility, and from processing back to the patient. When cells travel unfrozen, facilities can only be placed within reach of that limit. Gaudi Clinical has also started shipping cells on the Tokaido Shinkansen with the JR Central group, so it is attacking the same distance limit from both the container and the route.

The companies say tests in real operating conditions showed the pod could improve on-time arrival, reduce workload and make sample mix-ups less likely. In autologous therapy, returning one patient's cells to another is a far more serious failure than an out-of-specification result. Carrying one patient's cells per small container cuts the number of transfers and of boxes holding several patients' samples.

Buyers will still want answers on four points: the ambient conditions behind the 24-hour and 11.5-hour figures, whether their own routes stay within limits in midsummer and midwinter, how temperature loggers and excursion rules are written into procedures, and how the storage material is brought to temperature before departure.